Emergent BioSolutions (EBS) Change in Cash (2010 - 2026)

Emergent BioSolutions' Change in Cash history runs 17 years deep, the most recent figure standing at -$47.6 million for Q1 2026.

• On a quarterly basis, Change in Cash fell 200.85% year-over-year to -$47.6 million in Q1 2026; TTM through Mar 2026 was $8.7 million, a 88.21% decrease from a year earlier, with the FY2025 full-year figure at $103.5 million, up 1796.72% from the prior year.
• Change in Cash slipped to -$47.6 million in Q1 2026 per EBS's latest filing, from -$40.1 million in the prior quarter.
• Across five years, Change in Cash topped out at $401.6 million in Q4 2022 and bottomed at -$344.2 million in Q2 2023.
• The 5-year median for Change in Cash is -$32.7 million (2024), against an average of -$24.4 million.
• Across the five-year window, Change in Cash plunged 342.99% in 2023 and soared 10775.0% in 2024, its largest moves.
• Year by year, Change in Cash stood at $401.6 million in 2022, then sank by 94.05% to $23.9 million in 2023, then sank by 312.55% to -$50.8 million in 2024, then increased by 21.06% to -$40.1 million in 2025, then fell by 18.7% to -$47.6 million in 2026.
• Per Business Quant, the three latest EBS Change in Cash figures stand at -$47.6 million (Q1 2026), -$40.1 million (Q4 2025), and -$21.8 million (Q3 2025).